The pharmacokinetics of primaquine have been well defined in male volunteers, but there is little data on the disposition of the drug in women. We compared the kinetics of primaquine in nine male and nine female healthy Australian volunteers after the administration of a single oral dose (30 mg base) of primaquine. No statistical differences were observed in the following kinetic parameters of primaquine between men and women, respectively: maximum plasma concentration (93 +/- 26 and 115 +/- 38 ng/mL; 95% confidence interval [CI] of the mean difference: -55 to 10 ng/mL; P = 0.16), area under the curve (1.1 +/- 0.5 and 1.2 +/- 0.4 microg x h/mL; 95% CI: -0.6 to 0.3 microg x h/mL; P = 0.54), and clearance (0.34 +/- 0.12 and 0.39 +/- 0.14 L/h/kg; 95% CI: -0.17 to 0.08 L/h/kg; P = 0.46). The clinical relevance of such findings would suggest that sex does not have to be taken into account as a factor when prescribing primaquine for radical cure or terminal prophylaxis of Plasmodium vivax malaria.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pharmacokinetics primaquine
8
microg h/ml
8
primaquine
6
+/-
6
lack sex
4
sex pharmacokinetics
4
primaquine pharmacokinetics
4
primaquine well
4
well defined
4
defined male
4

Similar Publications

Article Synopsis
  • YAT2150 is a new antimalarial drug that shows promise for malaria treatment and diagnosis by increasing fluorescence upon entering cells and blocking key developmental stages in malaria pathogens.
  • The drug's effective uptake mechanisms and favorable pharmacokinetics make it a strong candidate for enhancing transmission-blocking strategies, especially when used in conjunction with immunoliposome encapsulation to reduce toxicity.
  • YAT2150 interacts preferentially with unstructured proteins in parasites, which may lead to decreased protein aggregation, a mechanism also seen with traditional antimalarial treatments, positioning it as a potential leader in innovative malaria therapies.
View Article and Find Full Text PDF

Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure.

Malar J

September 2024

MMV Medicines for Malaria Venture, 20 Route de Pré-Bois, 1215, Geneva 15, Switzerland.

Article Synopsis
  • * The World Health Organization's updated guidelines in October 2023 limit primaquine use in breastfeeding women, assuming it could harm infants with G6PD deficiency, although there's ongoing anticipation for tafenoquine recommendations.
  • * Recent studies argue for lifting primaquine restrictions due to findings showing very low infant exposure to the drug in breastfeeding scenarios, suggesting minimal risk to infants while highlighting the public health benefits of preventing malaria relapses in mothers.
View Article and Find Full Text PDF

Background: Primaquine (PQ) has activity against mature P. falciparum gametocytes and proven transmission blocking efficacy (TBE) between humans and mosquitoes. WHO formerly recommended a single transmission blocking dose of 0.

View Article and Find Full Text PDF

Primaquine (PQ) is a widely used antimalarial drug, but its high dosage requirements can lead to significant tissue damage and adverse gastrointestinal and hematological effects. Recent studies have shown that nanoformulations can enhance the bioavailability of pharmaceuticals, thereby increasing efficacy, reducing dosing frequency, and minimizing toxicity. In this study, PQ-loaded PLGA nanoparticles (PQ-NPs) were prepared using a modified double emulsion solvent evaporation technique (w/o/w).

View Article and Find Full Text PDF

In preparation for mass vaccinations with R21/Matrix-M™ combined with mass administrations of dihydroartemisinin, piperaquine, and a single low dose primaquine we assessed the tolerability, safety, and potential interactions of this combination affecting immunogenicity or pharmacokinetics. 120 healthy Thai volunteers were randomised to receive either antimalarials combined with vaccinations (n = 50), vaccinations alone (n = 50), or antimalarials only (n = 20). Three rounds of vaccines and antimalarials were administered one month apart.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!